Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 9Terminated 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 69Lymphoid 58Other hematologic neoplasm 27Gastrointestinal 8Thoracic 4Myeloid 3Genitourinary 3CNS 3Breast 3Other 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Dermatologic 1

Conditions

Neoplasms 1Melanoma 1Lung Neoplasms 1Diabetes Mellitus 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Nivolumab 25pembrolizumab 21Ipilimumab 15Temozolomide 13toripalimab 12Biopsy 10Imiquimod 8Cyclophosphamide 8Dacarbazine 7Blood Specimen Collection 7camrelizumab 6Chemotherapy, Adjuvant 6trametinib 5dabrafenib 5atezolizumab 5aldesleukin 5Gene Expression Profiling 5Cisplatin 5Aminolevulinic Acid 5fludarabine phosphate 4fludarabine 4durvalumab 4binimetinib 4apatinib 4Tomography, Optical Coherence 4Sorafenib 4Photochemotherapy 4Injections 4Bevacizumab 4tislelizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Dexamethasone × Dermatologic × Clear all
NCT04001725 2019-11-13

OPTIMAL

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Unknown
110 enrolled
BreastCNSDermatologicThoracic

Brain Neoplasms, Breast Neoplasms, Diabetes Mellitus, Lung Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡